Form 4: Jazz Pharma Director Exercises Options, Sells Shares

Jazz Pharmaceuticals plc Director Bruce C. Cozadd exercised stock options and subsequently sold a portion of his ordinary shares on November 26, 2025.

Summary

• Bruce C. Cozadd, a Director of Jazz Pharmaceuticals plc, engaged in transactions involving the company's ordinary shares.
• On November 26, 2025, Cozadd exercised options to acquire a total of 77,500 ordinary shares (76,689 non-qualified and 811 incentive stock options) at an exercise price of $123.36 per share.
• Following the option exercises, Cozadd sold a total of 77,500 ordinary shares in multiple transactions.
• The sales occurred at weighted average prices ranging from $177.272 to $179.7923 per share.
• After these transactions, Cozadd's direct beneficial ownership of ordinary shares stands at 393,332.
• The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction involving the exercise of options and subsequent sale of shares, often pre-planned under a 10b5-1 plan. It reflects a realization of value by the insider but does not inherently signal positive or negative company performance or future outlook.

Positives

• Director Bruce C. Cozadd exercised stock options, indicating a realization of value from previously granted equity incentives.
• The sale prices of the ordinary shares (ranging from $177.272 to $179.7923) were significantly higher than the exercise price of $123.36, indicating a profitable transaction for the insider.

Negatives

• The director sold a substantial number of shares (77,500), which could be perceived as a reduction in direct insider ownership, although it is part of a pre-planned strategy under Rule 10b5-1(c).

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe a director reducing direct shareholding, but this is often part of a pre-planned strategy (Rule 10b5-1(c)) and not necessarily indicative of a lack of confidence. The profitable exercise and sale could be seen as a positive for the director.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Stock Options, Share Sale, Beneficial Ownership, Bruce C. Cozadd, Equity Incentive Plan, 10b5-1 Plan